Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M.

Lung Cancer. 2019 Sep;135:161-168. doi: 10.1016/j.lungcan.2018.11.041. Epub 2018 Dec 1.

PMID:
31446990
2.

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo JM.

Clin Transl Oncol. 2019 Jul 31. doi: 10.1007/s12094-019-02191-y. [Epub ahead of print]

PMID:
31368078
3.

Thermal Liquid Biopsy (TLB): A Predictive Score Derived from Serum Thermograms as a Clinical Tool for Screening Lung Cancer Patients.

Rodrigo A, Ojeda JL, Vega S, Sanchez-Gracia O, Lanas A, Isla D, Velazquez-Campoy A, Abian O.

Cancers (Basel). 2019 Jul 19;11(7). pii: E1012. doi: 10.3390/cancers11071012.

4.

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P.

Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30.

PMID:
31319999
5.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW.

Clin Lung Cancer. 2019 May;20(3):e407-e412. doi: 10.1016/j.cllc.2018.12.022. Epub 2019 Jan 4.

6.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

PMID:
30535340
7.

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A.

N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31.

PMID:
30380365
8.

Lung cancer in Spanish women: The WORLD07 project.

Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12941. doi: 10.1111/ecc.12941. Epub 2018 Oct 2.

PMID:
30277293
9.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.

PMID:
30206164
10.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

11.

Radical parametrectomy after 'cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete.

Pareja R, Echeverri L, Rendon G, Munsell M, Gonzalez-Comadran M, Sanabria D, Isla D, Frumovitz M, Ramirez PT.

Gynecol Oncol. 2018 Jun;149(3):520-524. doi: 10.1016/j.ygyno.2018.02.015. Epub 2018 Mar 1.

PMID:
29482838
12.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.

BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7.

13.

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C.

Lung Cancer (Auckl). 2017 Oct 30;8:207-216. doi: 10.2147/LCTT.S138570. eCollection 2017.

14.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E.

Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28.

PMID:
28660482
15.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629
16.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

17.

Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain.

Garrido P, Sánchez M, Belda Sanchis J, Moreno Mata N, Artal Á, Gayete Á, Matilla González JM, Galbis Caravajal JM, Isla D, Paz-Ares L, Seijo LM.

Arch Bronconeumol. 2017 Oct;53(10):568-573. doi: 10.1016/j.arbres.2017.03.004. Epub 2017 Apr 14. English, Spanish.

18.

Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07.

Viñolas N, Garrido P, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Cancer Invest. 2017 May 28;35(5):358-365. doi: 10.1080/07357907.2017.1295461. Epub 2017 Mar 28.

PMID:
28350480
19.

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Salvador J, Aparicio J, Baron FJ, García-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Muñoz M, Puente J, Rivera F, Rodríguez CA, Virizuela JA, Martín M, Garrido P.

Clin Transl Oncol. 2017 Apr;19(4):525. doi: 10.1007/s12094-017-1628-z. No abstract available.

PMID:
28243989
20.

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer.

Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D.

Clinicoecon Outcomes Res. 2016 Dec 30;9:31-38. doi: 10.2147/CEOR.S121093. eCollection 2017.

21.

Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.

Isla D, Felip E, Viñolas N, Provencio M, Majem M, Artal A, Bover I, Lianes P, DE Las Peñas R, Catot S, DE Castro J, Blasco A, Terrasa J, Gonzalez-Larriba JL, Juan O, Dómine M, Bernabe R, Garrido P.

Anticancer Res. 2016 Dec;36(12):6647-6653.

PMID:
27919997
22.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.

Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R; Spanish Lung Cancer Group.

Clin Lung Cancer. 2017 Mar;18(2):178-188.e4. doi: 10.1016/j.cllc.2016.08.007. Epub 2016 Nov 9.

PMID:
27908619
23.

SEOM Clinical Guideline for bone metastases from solid tumours (2016).

Grávalos C, Rodríguez C, Sabino A, Seguí MÁ, Virizuela JA, Carmona A, Cassinello J, Isla D, Jara C, Martín M.

Clin Transl Oncol. 2016 Dec;18(12):1243-1253. doi: 10.1007/s12094-016-1590-1. Epub 2016 Nov 28.

24.

A consensus statement on the gender perspective in lung cancer.

Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, García-Campelo R, Juan O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MÁ, Cobo M, Paz-Ares L, Trigo JM, de Castro J.

Clin Transl Oncol. 2017 May;19(5):527-535. doi: 10.1007/s12094-016-1578-x. Epub 2016 Nov 24. Review.

PMID:
27885542
25.

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Salvador J, Aparicio J, Baron FJ, Garcia-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Munoz M, Puente J, Rivera F, Rodriguez CA, Virizuela JA, Martin M, Garrido P.

Clin Transl Oncol. 2017 Mar;19(3):341-356. doi: 10.1007/s12094-016-1535-8. Epub 2016 Aug 25. Erratum in: Clin Transl Oncol. 2017 Apr;19(4):525. multiple author names corrected.

26.

Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.

Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR.

Clin Lung Cancer. 2017 Jan;18(1):43-49. doi: 10.1016/j.cllc.2016.05.011. Epub 2016 Jun 4.

PMID:
27461773
27.

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.

De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D.

Clin Transl Oncol. 2017 Feb;19(2):219-226. doi: 10.1007/s12094-016-1527-8. Epub 2016 Jul 1.

PMID:
27371031
28.

Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.

De Castro J, García R, Garrido P, Isla D, Massuti B, Blanca B, Vázquez J.

Clin Lung Cancer. 2015 Nov;16(6):431-46. doi: 10.1016/j.cllc.2015.06.004. Epub 2015 Jun 25. Review.

29.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group.

JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.

PMID:
26181014
30.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators.

Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.

PMID:
26156651
31.

[Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology].

Ferreirós J, Cabeza B, Gayete Á, Sánchez M, Torres MI, Cobo M, Isla D, Puente J, Reguart N, de Castro J.

Radiologia. 2015 Jan-Feb;57(1):66-78. doi: 10.1016/j.rx.2014.10.002. Epub 2014 Dec 17. Spanish.

32.

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology.

de Castro J, Cobo M, Isla D, Puente J, Reguart N, Cabeza B, Gayete A, Sánchez M, Torres MI, Ferreirós J.

Clin Transl Oncol. 2015 Jan;17(1):11-23. doi: 10.1007/s12094-014-1231-5. Epub 2014 Nov 6.

PMID:
25373531
33.

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Felip E, Concha Á, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F.

Clin Transl Oncol. 2015 Feb;17(2):103-12. doi: 10.1007/s12094-014-1248-9. Epub 2014 Oct 29. Review.

PMID:
25351175
34.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.

Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27.

PMID:
25164908
35.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
36.

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.

Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E.

Thromb Res. 2013;132(6):666-70. doi: 10.1016/j.thromres.2013.09.026. Epub 2013 Sep 27.

PMID:
24491267
37.

Lung cancer in women: an overview with special focus on Spanish women.

Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de Castro J, Artal A, Sánchez MJ.

Clin Transl Oncol. 2014 Jun;16(6):517-28. doi: 10.1007/s12094-013-1137-7. Epub 2013 Nov 26. Review.

PMID:
24277573
38.

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.

Garrido P, Rosell R, Arellano A, Andreu F, Dómine M, Perez-Casas A, Cardenal F, Arnaiz Mdel M, Morán T, Morera R, Isla D, Valencia J, Cobo M, Delgado R, García-Gómez R, Calvo F, Zamora J, Ramos A, Massutí B.

Lung Cancer. 2013 Jul;81(1):84-90. doi: 10.1016/j.lungcan.2013.03.009. Epub 2013 Apr 21.

PMID:
23611405
39.

Zoledronic acid in lung cancer with bone metastases: a review.

Isla D, Afonso R, Bosch-Barrera J, Martínez N.

Expert Rev Anticancer Ther. 2013 Apr;13(4):421-6. doi: 10.1586/era.13.15. Review.

PMID:
23560837
40.

Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital.

Salvador J, Grávalos C, Albanell J, Barnadas A, Borrega P, García-Mata J, Garrido P, Gonzalez-Flores E, Isla D, Lomas M, Rodríguez-Lescure A, Cruz JJ, Alba E.

Clin Transl Oncol. 2012 Nov;14(11):820-6. doi: 10.1007/s12094-012-0873-4. Epub 2012 Aug 2.

PMID:
22855162
41.

Functions and workload of medical oncologists in Spain.

Grávalos C, Salvador J, Albanell J, Barnadas A, Borrega P, García-Mata J, Garrido P, González-Flores E, Isla D, Lomas M, Rodríguez-Lescure Á, Cruz JJ, Alba E; Spanish Society for Medical Oncology (SEOM).

Clin Transl Oncol. 2012 Jun;14(6):423-9. Review.

PMID:
22634530
42.

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

Garrido P, de Castro J, Concha Á, Felip E, Isla D, López-Ríos F, Paz-Ares L, Ramírez J, Sanz J, Gómez JJ.

Clin Transl Oncol. 2012 May;14(5):338-49. doi: 10.1007/s12094-012-0806-2.

PMID:
22551539
43.

Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben KK, Andrew AS, Bencko V, Bickeböller H, Boffetta P, Brennan P, Brenner H, Duell EJ, Fabianova E, Field JK, Foretova L, Friis S, Harris CC, Holcatova I, Hong YC, Isla D, Janout V, Kiemeney LA, Kiyohara C, Lan Q, Lazarus P, Lissowska J, Le Marchand L, Mates D, Matsuo K, Mayordomo JI, McLaughlin JR, Morgenstern H, Müeller H, Orlow I, Park BJ, Pinchev M, Raji OY, Rennert HS, Rudnai P, Seow A, Stucker I, Szeszenia-Dabrowska N, Dawn Teare M, Tjønnelan A, Ugolini D, van der Heijden HF, Wichmann E, Wiencke JK, Woll PJ, Yang P, Zaridze D, Zhang ZF, Etzel CJ, Hung RJ.

Eur J Cancer. 2012 Sep;48(13):1957-68. doi: 10.1016/j.ejca.2012.01.038. Epub 2012 Mar 19.

44.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
45.

Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine.

Provencio M, Isla D, Sánchez A, Cantos B.

J Thorac Dis. 2011 Sep;3(3):197-204. doi: 10.3978/j.issn.2072-1439.2011.01.02.

46.

MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, Kohlhaeufl M.

Lung Cancer. 2012 Jun;76(3):373-9. doi: 10.1016/j.lungcan.2011.11.020. Epub 2012 Jan 10.

PMID:
22236866
47.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.

PMID:
22197612
48.

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S, Spigel DR.

Ann Oncol. 2012 May;23(5):1111-20. doi: 10.1093/annonc/mdr463. Epub 2011 Nov 4. Review.

49.

SEOM guidelines on thrombosis in cancer patients.

Muñoz AJ, Viñolas N, Cubedo R, Isla D.

Clin Transl Oncol. 2011 Aug;13(8):592-6. doi: 10.1007/s12094-011-0703-0.

PMID:
21821496
50.

SEOM clinical guidelines for using molecular markers in clinical practice.

Arrazubi V, Pazo R, Isla D, Pérez Gracia JL.

Clin Transl Oncol. 2011 Aug;13(8):587-91. doi: 10.1007/s12094-011-0702-1.

PMID:
21821495

Supplemental Content

Support Center